May 2, 2019
Sanofi’s dengue vaccine approved in USA
Sanofi’s dengue vaccien Dengvaxia was approved in the USA, the company said in a press release Thursday.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
May 2, 2019
Axial Biotherapeutics develops AB-2004 as potential treatment for gastrointestinal dysfunction
– Preclinical results support development of AB-2004 as potential treatment for gastrointestinal dysfunction and associated behavioral symptoms of Autism Spectrum…
May 2, 2019
FSD Pharma delays 2018 Year-End Filings, working with new auditing firm in advance of listing on the NYSE
FSD Pharma delays 2018 Year-End Filings, working with new auditing firm in advance of listing on the NYSE
May 2, 2019
Vivera Pharmaceuticals names new Chief Medical Officer
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/CBD?src=hash” target=”_blank”gt;#CBDlt;/agt;–Vivera Pharmaceuticals, Inc., a pharmaceutical company focused on non-addictive pain management, today announced the appointment…
May 2, 2019
Dicerna™ to Report First Quarter 2019 Financial Results and Host Conference Call on May 9, 2019
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi)…
May 2, 2019
bluebird bio Reports First Quarter 2019 Financial Results and Highlights Operational Progress
– Received positive opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) gene therapy for patients 12 years…
May 2, 2019
bluebird bio Reports First Quarter 2019 Financial Results and Highlights Operational Progress
– Received positive opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) gene therapy for patients 12 years…
May 2, 2019
Gilead Sciences Announces First Quarter 2019 Financial Results
– Product Sales of $5.2 billion –– Diluted EPS of $1.54 per share –– Non-GAAP Diluted EPS of $1.76 per…
May 2, 2019
Ligand Reports First Quarter 2019 Financial Results
Conference Call Begins at 4:30 p.m. Eastern Time Today SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results…
May 2, 2019
Ligand Reports First Quarter 2019 Financial Results
Conference Call Begins at 4:30 p.m. Eastern Time Today SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results…